Skip to main content

Vertex Pharmaceuticals Inc

VRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000875320

In the last 90 days, Vertex Pharmaceuticals Inc insiders filed 0 open-market purchases and 4 sales; 1,763 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.

Holders of 5% or more of VRTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Vertex Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of VRTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Capital World Investors13G/A11.20%28.7M shares–Feb 13, 20251 filingFeb 13, 2025SEC
Capital Research Global Investors13G5.70%14.5M sharesNewMay 13, 20251 filingMay 13, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Vertex Pharmaceuticals Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on VRTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 27, 20261:54 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
May 13, 202511:32 AM ETCapital Research Global Investors13G5.70%14.5M sharesNewMar 31, 2025SEC
Feb 13, 20254:53 PM ETCapital World Investors13G/A11.20%28.7M shares–Dec 31, 2024SEC
Feb 12, 20259:34 AM ETFMR LLCand 1 other13G/A3.60%9.22M shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Vertex Pharmaceuticals Inc shares.

No Form 144 notices for Vertex Pharmaceuticals Inc are on file.